InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: dcaf7 post# 208

Tuesday, 01/31/2023 10:37:20 AM

Tuesday, January 31, 2023 10:37:20 AM

Post# of 581
1. "80 mg dose works better than 120 mg and 160 mg." Not sure we have enough data to support that. APTO has most complete picture and chose 120mg as the monotherapy starting dose with flexibility to go up or down. What's important to me at this point is the size of the therapeutic window.

2. Agree!

3. You jest! I am not yet convince about TP53mut. I would like to see at least a couple more. I think NRAS and NPM1 responses are pretty well established.

The data is what it is, encouraging, but not yet convincing.

I consider the montherapy data as an appetizer. I want to see combination data.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News